Devices, systems, and methods described herein relate to affecting an internal diameter of a body lumen, and, in many examples, of a pylorus. A silk-based bulking agent may be injected in a pyloric tissue so as to reduce an effective inner diameter of the pylorus. A multi-part occluding agent may be injected into a pylorus on the surface of the pyloric tissue to occlude the pylorus alone or in combination with the silk-based bulking agent.

A material or method that can serve as an alternative to a related-art digestive fluid leak preventative material and method of preventing a leak of a digestive fluid, the digestive fluid leak preventative material includes a self-assembling peptide gel, has an adhesion persistence ratio with respect to a collagen sheet of at least 40%, and has a decomposition ratio of 35% or less in pancreatic juice treatment at 37° C. for 7 days.

The present invention provides a kit for preparing a composition for sealing a lung tract, comprising: (a) a first component comprising: (i) a fibrinogen solution, and (ii) prewet gelatin particles in an aqueous solution; and (b) a second component comprising: (i) a thrombin solution, and (ii) a dry gelatin powder; wherein the first and second components are stored separately and configured for mixing together to form a composition that is flowable and cross-linkable. The composition may be used to seal tissue tracts such as lung tissue tracts.

A composite hydrogel contains alginate hydrogel and acellular matrix hydrogel. The ingredients used to produce the acellular matrix hydrogel contains acellular matrix and transglutaminases (TGases). The alginate hydrogel contains salginate complex. The alginate hydrogel and acellular matrix hydrogel constitute a three-dimensional crosslinking structure. The TGases can catalyze isopeptide bonding between acellular matrixes, and thus forms acellular matrix hydrogel through crosslinking.

A sealant syringe assembly includes a first syringe including a plurality of chambers and discharging a first solution which is a mixture of a buffer solution and compound powder; a reaction solution syringe including at least one chamber and discharging a reaction solution capable of reacting with the first solution; and a connector for connecting the first syringe and the reaction solution syringe to mix and discharge the first solution and the reaction solution. The first syringe includes three packing members provided inside the first syringe; a passage provided in the inner circumferential surface of the first syringe; and a plunger for providing a pressure to one of the packing members.

The invention relates to compositions comprised of albumin and clottable proteins including fibrinogen and to use thereof e.g., for treating bleeding. In particular, the compositions are comprised of albumin and one or more clottable proteins, wherein the albumin and the one or more clottable proteins are present at a total concentration of at least 90% by total protein weight, wherein the clottable protein fibronectin is present at an amount of less than about 0.5% by total protein weight or is absent, and wherein the weight ratio of the albumin to the clottable protein fibrinogen is at least 1:15, respectively.

The invention discloses a hemostatic composition comprising crosslinked gelatin in particulate form suitable for use in hemostasis, wherein the composition is present in paste form containing 15.0 to 19.5% (w/w), preferably 16.0 to 19.5% (w/w), 16.5 to 19.5% (w/w), 17.0 to 18.5% (w/w) or 17.5 to 18.5% (w/w), more preferred 16.5 to 19.0% (w/w) or 16.8 to 17.8% (w/w), especially preferred 16.5 to 17.5% (w/w), and wherein the composition comprises an extrusion enhancer.

Disclosed is a thrombin-free, liquid biological glue for therapeutic use, including fibrinogen and factor VIIa. The ratio of fibrinogen concentration to FVIIa concentration is 20000:1 to 1000:1, with the concentrations being expressed in weight per volume. The fibrinogen concentration is lower than 60 mg/ml. Also disclosed are a kit for preparing such a biological glue, a method to prepare the glue, and a medicament.

The present invention relates generally to agents and devices for promoting hemostasis and, more particularly, to bioresorbable hemostatic pads or patches releasably supported on non-resorbable scaffolds for ease of delivery in the field. A sealant and/or hemostat delivery device comprises a resorbable hemostatic pad having a wound facing side and an opposite back side, with a hemostatic and/or wound sealing agent disposed on the wound facing side; a non-resorbable scaffold having an attachment zone on said scaffold; wherein said hemostatic pad is releasably attached with the back side to the attachment zone. The bond between the scaffold and the resorbable hemostatic pad or wound dressing is either (i) severed prior to removal of the scaffold or (ii) is weakened due to the adhesive bonding them together being moisture-deactivated, or (iii) is released by mechanical disentanglement.

Biocompatible phase invertible proteinaceous compositions and methods for making and using the same are provided. Phase invertible compositions in accordance with the invention are prepared by combining a liquid proteinaceous substrate and a liquid crosslinking composition, where the liquid crosslinking composition includes a macromolecular crosslinking agent. Also provided are kits for use in preparing the subject compositions. The subject compositions, kits and systems find use in a variety of different applications.